首页> 外文期刊>Ophthalmology >SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type.
【24h】

SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type.

机译:SCORE研究报告2:研究者与视网膜静脉阻塞类型的阅读中心分类之间的观察员同意。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To evaluate interobserver agreement between investigator and Reading Center classification of retinal vein occlusion. DESIGN: The Standard Care versus COrticosteroid in REtinal Vein Occlusion (SCORE) Study includes 2 multicenter phase 3 randomized clinical trials evaluating the efficacy and safety of intravitreal triamcinolone: one involves participants with central retinal vein occlusion (CRVO) and one for participants with branch retinal vein occlusion (BRVO). Eyes with hemiretinal vein occlusion (HRVO) were classified as BRVO. PARTICIPANTS: A total of 682 SCORE Study participants, including 271 with CRVO and 411 with BRVO. METHODS: Participants were enrolled in each trial on the basis of investigator classification of retinal vein occlusion. Definitions of CRVO, BRVO, and HRVO based on clinical findings were specified in the study protocol. At baseline, 7-field color stereoscopic fundus photographs of the study eye of each participant were forwarded to the University of Wisconsin Fundus Photograph Reading Center (Reading Center) for evaluation. MAIN OUTCOME MEASURES: Percent agreement and kappa statistics comparing investigator and Reading Center classification of retinal vein occlusion type. RESULTS: With HRVO categorized as BRVO (consistent with the SCORE Study design), there was 98.0% agreement between investigator and Reading Center classification (641/654 eyes; kappa = 0.96; 95% confidence interval, 0.94-0.98). Disagreements were fairly evenly divided between classification of an eye as CRVO by the investigator and as BRVO by the Reading Center (7/13 disagreements) and vice versa (6 disagreements). When all 3 disease categories (CRVO, BRVO, and HRVO) were compared, there was 92.2% agreement (603/654; unweighted kappa = 0.86; 95% confidence interval, 0.83-0.90). Most disagreements (38/51, or 74.5%) were between BRVO and HRVO, with 9 between CRVO and BRVO, and 4 between HRVO and CRVO. In univariate analyses, baseline factors significantly associated with disagreement include larger area of capillary loss and black race; black race was the only significant factor in a multivariate analysis. CONCLUSIONS: Investigator and Reading Center agreement was excellent in the SCORE Study; disease classification would have been altered in only 13 eyes (2.0%) had Reading Center eligibility been required. Interobserver agreement was least for classification between BRVO and HRVO.
机译:目的:评估研究者与视网膜中心静脉阻塞的阅读中心分类之间的观察者之间的一致性。设计:视网膜静脉阻塞的标准护理与皮质类固醇激素(SCORE)研究包括2项评估玻璃体内曲安奈德的疗效和安全性的多中心3期随机临床试验:一项涉及视网膜中央静脉阻塞(CRVO)的参与者,另一项涉及分支视网膜的参与者静脉阻塞(BRVO)。患有半静脉阻塞(HRVO)的眼睛被分类为BRVO。参与者:共有682名SCORE研究参与者,包括271名CRVO和411名BRVO。方法:根据研究者对视网膜静脉阻塞的分类,将受试者纳入研究。研究方案中指定了基于临床发现的CRVO,BRVO和HRVO的定义。在基线时,将每个参与者的研究眼睛的7场彩色立体眼底照片转发到威斯康星大学眼底照片阅读中心(阅读中心)进行评估。主要观察指标:比较研究者和阅读中心对视网膜静脉阻塞类型的分类的一致性和κ统计。结果:将HRVO归类为BRVO(与SCORE研究设计一致),研究者与阅读中心分类之间的同意率为98.0%(641/654眼睛; k = 0.96; 95%的置信区间为0.94-0.98)。在研究者将眼睛分类为CRVO和在阅读中心将眼睛分类为BRVO时(7/13分歧),反之亦然(在6个分歧)。当比较所有三种疾病类别(CRVO,BRVO和HRVO)时,有92.2%的一致性(603/654;未加权的kappa = 0.86; 95%的置信区间0.83-0.90)。大多数分歧(38/51,或74.5%)是在BRVO和HRVO之间,其中9个在CRVO和BRVO之间,在4个在HRVO和CRVO之间。在单变量分析中,与分歧显着相关的基线因素包括较大的毛细血管丢失面积和黑色种族;黑色种族是多元分析中唯一重要的因素。结论:在SCORE研究中,研究者与阅读中心的协议非常出色。如果需要阅读中心资格,则只有13眼(2.0%)可以改变疾病分类。观察员之间的协议最少是BRVO和HRVO之间的分类。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号